A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing the Efficacy and Safety of Polatuzumab Vedotin in Combination with Rituximab and CHP (R-CHP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma

Principal Investigator

Craig Okada

Study Purpose

The purpose of this study is to compare the effects, good or bad, of polatuzumab vedotin in combination with four other drugs, rituximab, cyclophosphamide, doxorubicin, and prednisone (when given together, referred to as R-CHP); compared with vincristine in combination with R-CHP (referred to as R-CHOP) on you and your lymphoma, to find out which is better.

Medical Condition(s)

Diffuse Large B-Cell Lymphoma (DLBCL)

Eligibility Criteria

Men and women ages 18-80 with previously untreated DLBCL

Age Range

18 - 80

Healthy Volunteers Needed


Duration of Participation

You will be asked to take study treatment (R-CHP with polatuzumab vedotin and placebo instead of vincristine; or R-CHOP with placebo instead of polatuzumab vedotin) for approximately 18-24 weeks. The investigator will ask you to return to the clinic 4 to 8 weeks after your last dose of study treatment. Your total length of time in the study, including the screening, treatment, and follow-up periods, will be about 5.5 years.

Minors Included



Clinical Trials Information Line
Phone: 503-494-1080


Genentech, Inc., an affiliate of F. Hoffmann-La Roche Ltd.

Recruitment End


Compensation Provided


Go Back